CD22 Antibody [2D6] (FITC) | 98-677

CD22 Antibody [2D6] (FITC) | 98-677 | Gentaur UK, US & Europe Distribution

Host: Rat

Reactivity: Mouse

Homology: N/A

Immunogen: Splenic lymphocyte plasma membranes from CBA x C57 F1 mice

Research Area: Cancer, Stem Cell, Immunology

Tested Application: Flow

Application: CD22 Antibody [2D6] for use in flow cytometry and immunohistochemistry / immunocytochemistry assays.

Specificiy: CD22

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: N/A

Clonality: Monoclonal

Clone: [2D6]

Isotype: IgG1

Conjugate: FITC

Physical State: Liquid

Buffer: Supplied in PBS/NaN3

Concentration: 0.5 mg/mL

Storage Condition: Store vial at 2-8˚C

Alternate Name: Lyb-8, Leu-14, BL-CAM

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: CD22, also known as Lyb-8, is a heterodimeric transmembrane glycoprotein and a member of a structurally related group of immunoglobulin (Ig) superfamily domain-containing proteins called the sialoadhesin family. It is detected in the cytoplasm early in B cell development (late pro-B cell stage) , appears on the cell surface concomitant with IgD, and is found on most IgM+IgD+ mature B lymphocytes. Expression is lost with terminal differentiation of B cells and is absent on plasma cells. Activation of B cells via cross-linking of surface Ig increases CD22 expression. CD22 associates with the B cell receptor (BCR) complex and mediates intercellular adhesion. Its intracellular domain is phosphorylated after antigen receptor cross-linking and is involved in negative regulation of B cell activation.